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Abstract

Dengue Virus (DENV) is a flavivirus spread by mosquitoes that are endemic in tropic
and subtropic climates. It is the causative pathogen of Dengue Fever, Dengue Hemorrhagic
Fever, and Dengue Shock Syndrome. Besides mosquito transmission, DENV can also be
transmitted through blood transfusion. Due to the high expense and expertise needed to run tests
like ELISA and Polymerase Chain Reaction (PCR) based-assays for DENV detection, a rapid,
sensitive and cost effective gold nanoparticles mediated surface-enhanced Raman spectroscopy
(SERS) assay has been developed as an alternative assay to detect DENV. In this project, I
successfully produced a monoclonal antibody that specifically binds to DENV-2 from the HB46ATCC cell line. Using HiTrap™ Protein G HP columns, the antibodies were purified and
concentrated by SpinX centrifuge filters. Bradford assay was used to measure antibody
concentration, SDS-PAGE was used to detect possible protein contamination, and
immunostaining confirmed antibody specificity for DENV 2. The SERS results show that this
antibody can be used for specifically detection of DENV-2.
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Chapter 1: Introduction
Dengue virus (DENV) is a mosquito-borne virus that can cause dengue fever (DF) and
dengue hemorrhagic fever (DHF), which are two types of diseases that are prevalent in tropical
and sub-tropical regions, such as South America, Southeast Asia and Africa13. The World Health
Organization (WHO) has estimated DENV infects nearly fifty to one hundred million people
each year, which has increased thirty-fold within last fifty years13. While other reports have
estimated over three hundred million people are indeed infected with DENV every year3,20.
Nevertheless, these DENV incidences suggest an important need for development of effective
antiviral therapeutics and vaccines against DENV infection that are currently lacking.
DENV primarily spreads to humans by an infected mosquito bite. However, there are
also many reported cases of the virus being transmitted through blood transfusion 5,13,19. Despite
the astounding prevalence of DENV infections, there is currently no blood screening measure
implemented for DENV, which is partially due to a lack of sensitive, rapid, and cost effective
assays14,25. Surface enhanced Raman spectroscopy (SERS) utilizes a highly specific method of
analysis that can identify and differentiate small biological molecules, including bacteria and
cancer cells4,6. Briefly, SERS identifies biological fingerprints that are enhanced in the presence
of a metal nanoparticle surface, which makes this a promising alternative to traditional blood
screening tools, such as ELISA and quantitative polymerase chain reaction (qPCR)-based assays
of viral detection. The hypothesis of this study is that specific DENV antibodies can be used in
SERS-based detection of DENVs. Thus, it can provide a sensitive and cost effective tool to
detect DENVs in blood and blood products.
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Chapter 2: Literature Review
The field of microbiology aims to catalogue and research all forms of bacteria, archaea,
fungi and viruses28. Viruses have been classified as non-living organisms that contain genomic
information in the form of nucleic acid, either RNA or DNA, encased in a protein shell called a
nucleocapsid1. Viruses rely on the internal machinery of host cells to replicate their nucleic acids,
package their genomes, and release them from infected cells to infect neighboring cells, thus
propagating infection1. Viruses can be enveloped, meaning they have an outer membrane
surrounding the nucleocapsid, or they can be naked with no outer lipid layer1, and have multiple
morphologies that range from the small circular picornaviruses (30 nm) to large mimivirus (750
nm)1.
To begin the replication cycle, a RNA virus usually firstly infects a cell by binding to
surface cell membrane receptors, inducing viral uptake into the cell by multiple mechanisms,
including direct viral envelope to cell membrane fusion, or by receptor-mediated endocytosis1.
The viral RNA genome is released into the cellular cytosol and the virus begins to replicate its
genome using the available host replication machinery1. After all necessary proteins are available
to be assembled, and adequate viral genome copies are produced, new infectious viral particles
are formed and released from the host cell 1.
DENV belongs to the genus of flavivirus that consists of a group of positive-sense,
single stranded, enveloped, RNA viruses with approximately fifty nanometers in diameter1. The
infection cycle of DENV is initiated through a bite of a female mosquito taking a blood meal
from an infected animal reservoir host19. The infected mosquito can then transmit the virus to
another reservoir, and the cycle is continued (Figure 1)19,21.
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Figure 1. Transmission cycle of DENV. DENV is transmitted between zoonotic reservoirs
(primates) to hosts (humans) via the vector female mosquito. Indicated there are two cyclic
transmission patterns with DENV, a sylvatic/enzootic cycle and an epidemic cycle of viral
transmission, whereby DENV may have jumped to the enzootic cycle to the epidemic cycle
through the mosquito vector contracting the virus from an infected primate, and transmitting it to
a human host. Image adapted from Susan Jones, 2007.21
DENV is a reemerging flavivirus that causes significant morbidity worldwide19. In 2013,
it was estimated that 390 million people were infected with DENV, with 96 million showing
clinical or subclinical symptoms of diseases3. This is compared to previous estimates of 80 to
100 million DENV cases in 198819. This means that in a span of 25 years, the estimated burden
of infection has tripled, especially in areas where vector of DENV transmission, Aedes aegypti
resides7,19, therefore highlighting DENV as a global public health concern1.
DENV can cause three different diseases, ranging from mild Dengue Fever (DF),
Dengue Hemorrhagic Fever (DHF) to severe Dengue Shock Syndrome (DSS)3,15,16, however,
75.4% of reported infections are asymptomatic4. DF consists of flu-like symptoms, including
headache, body pain, high fever, myalgia, and a rash, while DHF, along with the symptoms of
DF, is accompanied by the increased permeability of blood vessels, which can lead to severe
3

internal bleeding and substantial water loss. Furthermore, DSS is characterized by extreme blood
and water loss resulting in subsequent shock, which could be fatal if not treated immediately17.
Although DF is commonly observed during primary infection of DENV, incidence of DHF and
DSS increases during primary or secondary infection with other DENV serotypes17.
Although the immune response against DENV is not completely understood, it can be
categorized into two parts: primary infection and secondary infection, with the latter involving
antibody-dependent enhancement (ADE). There are four known DENV serotypes (DENV1-4)
that originated in monkeys in Africa or Southeast Asia approximately 100-800 years ago34. Upon
primary infection by DENV, the human immune system undergoes both cell-mediated and
humoral immune responses. The virus is first taken up in skin-resident Langerhans cells and
macrophages of the innate immune system and viral antigens are displayed on major
histocompatibility complex (MHC) molecules, which present viral antigen peptides to T cells to
mediate the cellular immune response14. This includes lysis of viral-infected cells via CD8 T
cells, natural killer cells, and macrophages14. Humoral immunity is initiated against DENV by Blymphocytes involvement in binding or engulfment of viral antigens, followed by
communication with macrophages and helper T cells, which differentiated the B cell into a
DENV-specific antibody secreting plasma cell, releasing immunoglobulins, such as IgM, IgG
and IgA to generate immune complexes for subsequent infection14. Immunoglobulins
(antibodies) are proteins that consist of two heavy and two light protein chains bonded together
by disulfide bonds (Figure 2)7. Each antibody has a conserved constant region (Fragment
constant, Fc) and a variable region (Fragment antigen-binding, Fab), which is specific to the
challenging antigen, on both the heavy and light chains7,14. The antigen binds to the Fab region,
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forming an immune complex to aid in viral clearance and protection against subsequent
infections against the same virus7,14.

Figure 2. Construction of an antibody. Image represents an immunoglobulin G (IgG), that
contains two heavy chains (pink/red) that contain and fragment constant (Fc) region, and two
light chains (green). Fragment antigen binding (Fab) regions are indicated on both heavy and
light chains containing hypervariable regions. Both chains are connected via disulfide bridges
(yellow). Image adapted from Flint, 2000.6

Once the primary infection is cleared, some of CD8 T cells and B cells become memory
cells resulting in lifelong immunity against the particular viral infection14. In case of DENV
infections, the lifelong immunity is only specific against one type of DENV. Therefore, if an
individual is exposed to a different DENV serotype during a secondary infection, the antibodies,
such as IgG, against the first serotype don’t fully neutralize the second DENV, but instead
binding to Fc-receptors on immune cells particular monocytes and macrophages paradoxically
enhancing infection leading to DHS/DSS, which is called as ADE22. In addition, anti-DENV
IgG, IgM and complement C3 receptors have also been described to aid in ADE formation, as
well22. Moreover, increased mononuclear cell activity releases a “cytokine storm,” whereby an
5

over production and release of cytokines and chemokines that can lead to non-specific
inflammation, which can result in increase of epithelial cell permeability contributing to vascular
leakage and internal bleeding during in DHF and DSS17,22. Reports indicated that ADE increases
risk for DHF and DSS, so there is a critical need for highly specific and rapid identification of
DENV serotypes in donated blood before transfusion15,17,26.
The presence of virus in the blood (viremia) increases during the incubation phase, peaks
during the symptomatic phase, and slowly decreases as the immune system clears DENV from
the body10. DENV viremia has been detected in asymptomatic patients five to seven days post
symptoms in ranges of 3 to 7.4 x 1013 plaque forming units (PFU)17-20. This poses a severe threat
in the context of donated blood and organs. Within the past ten to fifteen years, increasing
reports have identified DENV transmission through blood transfusions and organ
transplantations within endemic areas5,12,18,20. Due to variability of DENV symptoms, blood and
organ donors may have unknowingly DENV infection 23. In a study surveying donations in
Puerto Rico, the results of polymerase chain reaction (PCR/qPCR) analysis of blood showed 56
viremic donations per 77,000 yearly donations collected20. In addition, studies in Australia,
Brazil, and Honduras also showed similar results, indicating the global need for DENV blood
screening19.
There have been some assays performed to measure DENV in blood donations, including
through DENV NS1 Ag screening, whereby anti-DENV antibodies in the blood implies previous
infection26. However, this assay is not very specific and cannot differentiate acute from previous
DENV infection, thus not useful to screen blood samples for viral particles26. The current gold
standard for DENV detection in blood is through PCR, a highly specific viral genome detection
assay13. Two PCR methods are currently performed, including nested PCR and traditional PCR.

6

While these assays are both serotype specific and highly sensitive, detecting as little as 10 PFU
per ml12, both processes take at a few hours to perform respectively12-13. PCR also requires nonportable, specialized equipment, trained technicians and costly reagents.
Surface-enhanced Raman spectroscopy (SERS) is a type of vibrational spectroscopy that
uses gold nanoparticles (AuNP) to enhance a Raman signal to multiple powers of magnitude23.
AuNPs are conjugated to a molecule-specific probe and excited by the Raman signal which
relays a “molecular fingerprint” of the small biological molecule called the “analyte” 23. Dr.
Fengwei Bai’s group has determined a flaviviral antibody (4G2)-AuNP complex that can bind to
the DENV-2 and forms a specific DENV fingerprint using SERS10 (Figure 3). SERS could be an
alternative to the PCR based assays of DENV detection in blood as it is cheap, easy, and rapid to
perform, taking as little as ten seconds per spectra sample10. Therefore, the full assay takes
around “30 minutes from viral incubation with AuNP-4G2 to SERS sensing”23. Additionally, it
is a very sensitive assay as it can detect as few as 10 PFU per 1 ml of sample, which is
comparable to most standard assay, like PCR12,23.

Figure 3. Proposed schematic of Bio-conjugation of anti-DENV2 IgG (HB46) to gold
nanoparticles (AuNP). AuNPs are incubated with polyethylene glycol (PEG) and is bound via
Au-Sulfur interaction. Purified HB46 IgG js then incubated with the AuNP-PEG via -COOH end
binding to the thiol (S) acid. Estimates of approximately 100 IgGs can be bound to 1 AuNP (Paul
et al., 2014)24.
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Early experimental issues using SERS was due to these non-specific reactions with biological
materials; since then, several studies have focused on this issue, and have found that binding a
specific “bio-recognition agent” to the nanoparticle can resolve these issues tremedously6,11,23.
To do this, the majority of groups used a complex of thiolated polyethylene glycol (HS-PEG),
which works to bind the AuNP surface to sulfur, stabilizing the nanoparticles4,6,11,23. Dr. Bai’s
group has used flavivirus specific antibodies to serve as the recognition agent, showing that
antibody-antigen reactions could be used to make a DENV-specific SERS assay23. This method
depends upon the antigen-antibody binding in the Fab region of the antibody to excite the now
unstable magnetic fields when exposed to the SERS signal4,6,11,23. The movement of the bonds in
the magnetic field are measured, resulting the spectra readout4,6,9,23. Without this complex, the
antibody-PEG-AuNPs are stable and do not move, failing to provide the magnetic field that is
utilized in SERS fingerprinting4,6,9,23. These results not only show that the SERS assay is very
specific, but also the assay is very sensitive to detect as little as 10 PFU per ml (PFU/ml) DENV
concentration23. Using antigen-specific antibodies ensures the specificity of the SERS complex
by preventing multiple antigens from binding to the AuNP complex21 and is especially useful for
differential DENV serotype testing, which can be utilized in diagnostics. Moreover, this study
also tested the reproducibility of the SERS spectra, and found that there was minimum shift
between the peaks during multiple runs (Figure 4)23. Using this study as guidance, the purpose of
this thesis is to produce specific DENV-2 antibodies (HB46) for the use of SERS applications,
such as detection of specific DENV serotypes in blood donations and/or be used in diagnostics.
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Figure 4. SERS viral vingerprints using AuNP-anti-flavivirus (4G2) antibodies. A. SERS
viral fingerprint of DENV-2 indicates multiple surface-functional groups; B. Viral dilutions of
DENV-2 followed by SERS assay indicates DENV-2 fingerprint is sensitive to detected 10
DENV-2 per 1 ml of sample; C. SERS DENV-2 fingerprint is reproduced after multiple runs
(n=5). Image adapted from Paul et al., 201523.
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Chapter Three: Methods and Materials

3.1. Experimental outline overview. Briefly, specific DENV-2 antibodies (HB46) were produced
in mouse cell culture and these antibodies were then purified and concentrated to be
subsequently conjugated to AuNPs to be used for SERS analyses in future studies. For this,
DENV-2 antibodies were generated, purified and concentrated in a biosafety level (BSL) II
facility at the University of Southern Mississippi (USM), while conjugation of these purified
DENV-2 antibodies to AuNPs (AuNP-IgG) will be performed at Jackson State University (JSU)
under the direction of Dr. Paresh Ray. For this, AuNP-HB46 will be cultured in the presence of
various DENV1-4 dilutions in buffer by trained personnel at USM, and analyzed by SERS at
JSU. Collaboration between institutes is instrumental to the future success of these experiments.

3.2. Isolation and Purification of DENV-2 antibodies. DENV-2 antibodies were produced
through cell culture under an aseptic techniques and a BSLII cabinet, which involved growing an
adherent cell line of HB46 (purchased from American Type Cell Culture, 3H5-1) in optimal
growth conditions. HB46 are a mouse hybridoma cell line that has fused myeloma cells with B
lymphocytes isolated from the spleens of mice that were immunized with DENV-2 antigens.
Under serum free media conditions, HB46 cells divided and secreted DENV-2 antibodies into
the media until a confluence (concentration) of cells that covered approximately ninety to ninetyfive percent of the cell culture plate was reached and the media turned a yellow-orange color
(low pH). This color change signifies expenditure of nutrients and the presence of increased
metabolites. To re-culture the cells and to collect the antibodies in media, adherent cells were
removed by scraping the bottom of the culture flask, were transferred to a 50 ml conical tube and
were centrifuged at 2500 revolutions per minute (rpm) for 5 minutes to pellet the viable cells,
10

while secreted antibodies remained in the supernatant. The supernatant containing DENV-2
antibodies were isolated and stored at -20°C, and 10 ml of fresh, serum free media was added to
the pelleted cells. The cells were then re-cultured at 1x106 cells/ml and were incubated at 5%
CO2 in 37°C.
After about one liter of supernatant was collected, DENV-2 antibodies were concentrated
and purified. Purification was performed using HiTrapᵀᴹProtein G HP columns (GE Healthcare),
which are specifically designed to bind to IgG antibodies in supernatant due to the charge of the
molecules. All other media components passed through the column. Briefly, supernatant was
centrifuged (1500 rpm for 5 minutes) to remove any particulates that may have formed during a
freeze-thawing cycle, followed by dialyzation with phosphate buffered saline (PBS) to adjust the
supernatant to a neutral pH (pH~7). The columns were attached to a peristaltic pump apparatus
and rinsed through with PBS and 20 mM sodium phosphate (pH~7) (used to aid in the binding of
IgG proteins within the column). A peristaltic pump is a tool used for antibody purification
procedures as the rate of flow of supernatant can be tightly controlled through a relatively slow
process, whereby supernatant would be introduced into the column at about a milliliter per
minute. When 100 ml of medium was passed through the column (containing IgG) was eluted
with 0.1 M glycine (pH~2) solution. Glycine at a pH of 2 was used, as this low pH is able to
break the disulfide bonds of the antibodies (Figure 2), briefly, to elute them out of the column.
Buffer neutralization is quickly achieved as the eluted solution was mixed with 500 mM of TrisHCL (pH~8), which re-associated the broken antibody subunits. Elutes were stored at 4°C until
concentration steps were performed.
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3.3. Concentration of purified DENV-2 antibodies. After being stored, elutes were concentrated
using a Corning Spin-X UF® concentrator column, which consists of a filter subunit (100 kD
mw) attached to a flow-through receptacle underneath. The spin column was first prepped with
5ml of 20 mM sodium phosphate and incubated for 5 minutes. Purified elute (10 ml) was then
added to the spin column and was centrifuged at 1500 rpm for 2 minutes (3x), with the
replacement of flow-through (~5 ml) back to the filter subunit with each individual spin,
followed by an additional spin at 2500 rpm for 15 minutes to ensure maximum concentration
was reached. The remaining liquid in the top of the concentrator contained DENV-2 antibodies,
which did not filter through due to their size (150 kD), were mixed with 40% glycerol to a final
concentration of 1 mg per ml and were stored at -20°C in 100 µl aliquots.

3.4. Determining the concentration of purified DENV-2 antibodies. DENV-2 antibody
concentrations were measured using a Bradford assay and a mouse IgG standard (1.2 mg/ml) as a
control. Briefly, the Bradford assay consists of using a Bradford dye (Bio-Rad) that changes
color from brown to blue in the presence of protein detection. This color change is in direct
relation to the concentration of protein in the sample, which can be measured by spectroscopy
(Bio-Rad SmartSpecTM 3000). Unknown HB46 IgG samples were then compared to a standard
mouse IgG control and concentration of the unknown HB46 IgG was determine by equation 1.

3.5. Determining purity of DENV-2 antibodies. To confirm our DENV-2 antibodies are pure,
and do not contain proteins, a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) was performed to separate the antibodies. Briefly, 10% SDS pre-made casted gels,
purchased from Bio-Rad, were used for protein separation. DENV-2 antibodies ran in parallel
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with a mouse IgG standard control (0.6 mg/ml). Antibodies were treated with β-Mercaptoethanol
(β-ME), which is a reducing agent that aids in breaking the disulfide bonds between the heavy
and light chains of the antibody, identifying the heavy and light chain sizes (50 kD and 25 kD,
respectively). A kaleidoscope protein ladder (Bio-Rad) was used, and the antibodies were
serially diluted from 1.3 mg/ml to 0.013 mg/ml for SDS-gel detection.
To prepare the apparatus for SDS-PAGE, the pre-made casted gel was placed into an
electrophoresis chamber, with 1x Running Buffer (25mM Tris, 192 mM glycine, 0.1% SDS, 10x
Bio-Rad) was added. 10 µl of each IgG sample was mixed with 2x Laemmli sample buffer (BioRad) and 15% β-ME and were boiled for 10 minutes. The antibodies were then added to each of
the pre-cast wells, along with a standard protein ladder, and ran for about 1 hr at 200 A/60 V, or
until the running buffer front was at the bottom of the gel. The gel was then was rinsed with
double distilled water (H2O) for five minutes (2x), then treated with a fixation solution (40%
methanol, 10% acetic acid) for five minutes. After fixation, the gel was treated with a nonspecific protein staining solution (0.025%(w/v) Coomassie Blue G-250, 10% acetic acid) for 15
to 30 min while gently shaking on a Stovall “The Bell Dancer” Orbital Platform shaker. The gel
was then destained with the fixation solution and imaged on a Bio-Rad ChemiDocTM MP imager
in the Mississippi INBRE facility.

3.6. DENV-2 Immunoassay. To determine if DENV-2 antibodies successfully detect DENV-2
antigens, immunoassays were performed. For this, Vero cells, an African green monkey kidney
epithelial cell line that is fast growing and anchorage dependent, were infected with DENV-2 at
multiple viral dilutions (stock = 3.5x106 PFU/ml) to determine sensitivity of DENV-2 antigen
detection. Briefly, Vero cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM)
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supplemented with 10% fetal bovine serum (FBS) in 5% CO2 at 37° C and plated at a
concentration of 1x106 cells/ml for 24 hr. Following incubation, cells were infected with DENV2 virus (ATCC), by certified personnel for 1 hr for viral adsorbtion and penetration into the cells,
followed by a wash with DMEM+10% and addition of the overlay media (DMEM+2%FBS and
1% Methyl Cellulose) for 4 days to allow for viral amplification and foci formation. After 4
days, cells were washed in PBS, and fixed with 4% paraformaldehyde (PFA) for 15 minutes at
room temperature. Cells were then washed two times with PBS, and incubated with purified
DENV-2 antibodies (1:100) overnight at 4°C. Secondary anti-mouse IgG antibodies conjugated
to horseradish peroxidase (HRP) was then added (1:1000) for 2 hr at room temperature, and
colorimetric detection was produced by the addition of True Blue Peroxidase substrate for focal
forming unit (FFU) imaging. Images were taken with a ChemiDocTM MP imager.
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Chapter Four: Results
4.1. DENV-2 antibody concentration measurements
DENV-2 antibodies were collected from mouse HB46 cells and were purified using
HiTrapTM Protein columns as described in the methods. Cells were then concentrated using
Corning Spin-X UF® concentrator as described in the methods and their concentrations were
determined using a Bradford assay (Table 1). A Bradford assay detects non-specific protein
concentration in samples through colorimetric detection using spectroscopy. Absorbance at a
wavelength of 595 nm was measured for each unknown concentration sample and a known
standard IgG sample was recorded. 40% glycercol was added to each sample for -20°C storage
conditions, then absorbance was measured a second time. Total sample concentration was
determined by the formula in equation 1. These results indicate that the concentration technique
was reproducible; as there was an expected loss of concentration after the addition of glycerol.
However, because the final concentrations maintained about 1.1 mg/ml, the process was
successful.

Table 1. Bradford assay concentration calculations Multiple experiments (n=3) were perform
to collect more than 1 mg/ml of purified antibody. A Bradford assay was performed to determine
the concentration of the purified HB46 IgG in each example indicated above. Sample
concentration calculations of DENV-2 antibody concentration were determined using equation 1,
below. Control denotes standard IgG, BR denotes Bradford readout at an absorbance of 595 nm,
AU denote arbitrary units.
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𝑼𝒏𝒌𝒏𝒐𝒘𝒏 𝒔𝒂𝒎𝒑𝒍𝒆 𝒂𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆

𝒎𝒈

= [𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅 𝒔𝒂𝒎𝒑𝒍𝒆 𝒂𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆𝟓𝟗𝟓 ] 𝑿 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅 𝑰𝒈𝑮 ( 𝒎𝒍 )
𝟓𝟗𝟓

Equation 1. The equation used to convert Bradford spectrometry at an absorbance of 595
nm to concentration (mg/ml). Determining the concentration of unknown samples was measured
by using the standard absorbance measurement (wavelength of 595 nm) and standard
concentration and the above formula.

4.2. DENV-2 antibody identification by SDS-PAGE
Following antibody Bradford concentration determination, samples were subjected to
SDS-PAGE identification to confirm the samples contained antibodies, and no other
contaminates present. Purified and concentrated HB46 samples were subjected to reducing β-ME
conditions to dissociate the heavy and light chains of the antibodies and were separated using an
SDS-PAGE. Heavy (50 kD) and light (25 kD) chains in lane 3 of a HB46 sample were compared
to a lane 2 standard IgG sample control, which indicated similar identification banding patterns,
without additional bands observed in HB46 samples, suggesting HB46 samples were pure IgG.
The Kaleidoscope Bio-Rad ladder is observed and compared 0.6 mg/ml IgG standard to 1.3
mg/ml sample of concentrated antibody (Figure 5).
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Figure 5. SDS-PAGE for IgG identification. Banding patterns of IgGs in order from left to right:
the BioRad Kaleidoscope™ Ladder (10 kD to 250 kD); Lane 1, (blank) β-ME treated buffer with
PBS without IgG, Lane 2, 0.6 mg/ml mouse IgG standard control treated with β-ME and Lane 3,
1.3 mg/ml HB46 IgG treated with β-ME.

4.3. Verification of DENV-2 antibody specificity to DENV-2 by an immunostaining assay
To confirm antibody specificity against DENV-2, immunostaining assays were
performed using differential DENV (1-4) types. Comparisons were made with anti-flavivirus
antibody (4G2, ATCC 3H5-1), which confirmed protocol reproducibility, while HB46 isolated
antibodies were used to determine specificity to DENV-2 (Figure 6).

Figure 6. Comparison of HB46 IgG specificity with 4G2. A. To confirm DENV-2 antibodies
were specific to DENV-2, a FFU assay of all four serotypes of DENV (labeled above) was
performed with flavivirus-specific antibodies (4G2). B. A FFU assay was performed with DENV2 serotype and HB46 (DENV-2 specific) in duplicate.

An additional FFU assay was performed to determine HB46 antibody sensitivity. For
this, DENV-2 was serially diluted, followed by an immunostaining assay using HB46 antibodies
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(0.013 mg/ml) (Figure 7.) Counted FFU are indicated in Table 2, which indicated HB46 could
successfully resolve a 1000x-diluted sample of DENV-2.

Figure 7. HB46 is highly sensitive to detection of DENV2. DENV2 dilution series and
immunostaining images are represented, from left to right: well 1, 1/10 dilution; well 2, 1/100
dilution; well 3, 1/1000 dilution; well 4, no virus control. The wells were performed in triplicate,
with best representation image reported. FFU are indicated as dark circles where HB46 antibodies
have bound to the DENV-2.

Dilution Factor
101
102
103

No. of Foci per well
143
28
10

Table 2. Sensitivity of HB46 detection of DENV-2. Counted foci per dilution factor indicated
reduced foci with increased DENV-2 dilution (101, 1/10 dilution, 102, 1/100 dilution, and 103,
1/1000 dilution of virus) and HB46 could detect as little as 1000x-diluted sample using an
immunostaining assay.
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Chapter Five: Discussion

The overall goal of this study is to produce and purify DENV-2 specific antibodies for
future SERS applications. In brief, DENV-2 antibodies (HB46) were produced in cell culture,
purified and concentrated, and tested for DENV-2 specificity in FFU assay. In future studies,
these specific antibodies will be conjugated to AuNPs, incubated with DENV-2, and subjected to
SERS analysis. The SERS assay will provide a sensitive, selective and rapid DENV-2 fingerprint
detection for diagnosis and blood screening.
The HB46 cell line was grown to confluence to produce antibodies against DENV-2.
Serum free media was an optimal growth medium to use for these cultures as antibodies that are
grown in serum would produce non-specific SERS fingerprint spectra4. This is because serum
contains multiple proteins, including non-specific antibodies, resulting in protein contamination,
which affects downstream SERS signaling. Once enough medium was produced, antibodies were
collected in columns that were used to purify and collect the IgG specific antibodies. HiTrapTM
columns utilize G proteins bound to a biocompatible polypropylene32. These proteins bind to the
Fc region of the IgG, causing the antibodies to bind to the column proteins and allowing all other
antibody types or contaminating proteins to pass through the column, yielding only the IgG
antibodies after elution32. A glycine buffer (pH~2) was used to break the strong bond between
the G protein in the column, while dissociating the disulfide bonds of the antibodies. However,
rapid buffer neutralization was achieved following elution in 500 mM Tris-HCl, which retain
neutral pH and prevented any additional IgG denaturation by the glycine buffer31.
A Bradford protein assay is one of the most commonly used protein quantification
methods used in research labs29. While there are more accurate quantification assays, such as the
Lowry method, the Bradford assay provides a rapid and more sensitive way to quantify protein
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without the use of many reagents29. The assay uses the color change of Coomassie dye (Bradford
Reagent) from brown to blue, signifying protein binding to the dye, to approximate the
concentration of protein in the solution, which is assumed to be directly proportional to the
spectroscopy readings29. The anionic blue form of the dye has a maximum absorbance of 590,
but most assays are measured at 595 due to a recorded absorbance shift once the protein has
bound to the dye29. IgGs are somewhat fragile in that they can easily denature in room
temperature conditions, so the speed and specificity of the Bradford assay provided was the
optimal choice compared to other quantification methods that take longer and require many more
reagents, which may possible even result in the introduction of contaminants. One drawback of
the Bradford assay is that it detects all proteins, not just antibodies, so while the concentration
can be assumed by the assay, the purity of the sample cannot29. To address this issue, we
performed an SDS-PAGE to check for any protein contamination.
To check the purity of the eluted IgG, SDS-PAGE was performed on the IgG sample and
an IgG standard control. The reducing agent β-ME was used to reduce the IgG from a tertiary
molecular structure (150 kD) to a primary structure that consists of two heavy chains (50 kD)
combined with two light chains (25 kD). β-ME can break the disulfide bonds separating the
chains, while separation of these chains are determined by SDS-PAGE, and compared to known
IgG controls for identification. Therefore, additional banding patterns observed in the SDSPAGE would serve as non-specific protein contamination. In our results, the IgG standard
reduced to 50 kD and 25 kD sizes, while our HB46 IgG samples had a slightly higher band
shifting around 28 kD. Upon further review, the light chains of monoclonal antibodies are known
to have a range of molecular weights (20 kD to 30 kD) upon reducing treatment7. Knowing that
the standard was pure and properly concentrated, the secondary banding was not contamination,
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but in fact most likely a result of possible incomplete reduction by the β-ME. Excluding the
secondary banding of the antibodies, there were no other bands in the gel, therefor there was no
extra-protein contamination in the concentrated antibodies.
DENV-2 antibodies must successfully bind to the virus for SERS viral fingerprinting
accuracy and selectivity. To ensure HB46 antibodies were capable of binding to DENV-2, a
focus forming unit assay (FFU) was performed. To compare the FFU identification of HB46, this
assay was first performed using a flavivirus-specific antibody (4G2) that can detect all 4
serotypes of DENV23. The results showed that HB46 IgG are capable of identifying DENV-2, as
compared to 4G2 IgG, which suggest HB46 IgG are selective for DENV2. Additional studies
using all serotypes of DENV (1-4) and HB46 in a FFU assay would further confirm the
selectivity of HB46 to DENV2, compared to DENV1, 3, or 4, which is planned for the near
future. Selective identification of different DENV serotypes in blood donations becomes useful
during a SERS assay for diagnosis and the prevention of ADE occurring in patients who have
already been infected with DENV. This selective DENV serotype testing could also allow health
care professionals and epidemiologists to identify infection trends and prevent further infection
in endemic areas.
Additionally, the immunostain results using 4G2 indicated differential sizes of FFU are
produced with each serotype of DENV. Studies have shown that serotypical differences can be
detected through FFU due to the reaction of the antibodies to each different antigen, with some
be more active than others, with the more active antigens creating larger and the less active
antigens creating smaller foci9. Further identification of HB46 sensitivity was performed using
serial dilutions of DENV-2, which suggests the sensitivity of HB46 antibody to detect virus,
using an immunostaining assay was 3.5x103 PFU/ml. During SERS, the sensitivity of HB46
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would be increased since multiple IgGs are conjugated to an AuNP, and it has been shown that
AuNP-4G2 complexes can detect as low as 10 PFU/ml of sample23. In brief, HB46 IgG samples
were capable of detecting 10 FFU/ml of DENV2, therefore are optimal to use for AuNP
conjugation and subsequent SERS applications.
Further directions for this study is to perform a SERS assay using specific HB46 IgGs
bound to AuNPs. For this, serial dilutions of DENV-2 will be performed in blood followed by the
addition of AuNP-HB46 complexes, and following an incubation period these samples would be
subjected to SERS. To confirm HB46 specificity, we will also dilute other flaviviruses, such as
WNV or Zika virus, in blood and add our AuNP-HB46 complexes to be subjected to SERS, which
would determine if SERS can provide a viral fingerprinting database for public use. Previous
studies have used 4G2 antibodies conjugated to AuNP complexes, but these antibodies are only
specific for flaviviruses in general and does not detect specific DENV serotypes which could be
useful for diagnostic purposes23. By using a SERS assay that is antigen specific, the diagnostic
aspect could be introduced, whereby a DENV-infected patient could know which serotype of
DENV they have, along with how much viremia is in their body (indicating the stage of infection),
and aid in their doctor’s course of treatment. It will also give blood banks more cost effective,
rapid and selective tools to screen for the DENV in endemic areas. This is especially useful in
these areas where cheaper equipment is feasible to use, while it is also less labor intensive than
RT-PCR. This allows for blood banks to test large amounts of samples in very little time, making
it an ideal tool for endemic areas.
In summary, since different viral spectra are generated for each virus type in a SERS assay,
this study provides a successful and reproducible protocol to initiate the development of an
alternative method of blood screening that is sensitive, rapid and cost-efficient. Therefore,
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generation of DENV-2 specific antibodies can be reproduced using this established protocol with
other DENV serotypes, which can be integrated into future AuNP conjugation designs and SERS
analyses.
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